Ask AI
ProCE Banner Activity

How I Manage Mantle Cell Lymphoma Using BTK Inhibitors: A Case Study From My Practice

Clinical Thought
Expert commentary on managing relapsed mantle cell lymphoma with Bruton tyrosine kinase inhibitors and mitigating treatment-related adverse events.

Released: March 07, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Christopher R. Flowers, MD, MS

Division Head, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine
MD Anderson Cancer Center
Houston, Texas

Christopher R. Flowers, MD, MS, has disclosed that he has received consulting fees from AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Genentech/Roche, Genmab, Gilead Sciences, Janssen, Karyopharm, Pharmacyclics, Seattle Genetics, and Spectrum and funds for research support from 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD, Genentech/Roche, Gilead Sciences, Guardant, Iovance, Janssen, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, and Ziopharm.